The purpose of this study was to investigate a putative role for cholecystokinin (CCK) in the activation of the hypothalamic-pituitary-adrenal (HPA) axis following intraperitoneal (i.p.) administration of interleukin-1-beta . Previous studies predict that CCK A receptors on vagal sensory afferents may be involved in the initiation of the stress response following an acute i.p. injection of IL-1b. Adult male rats were given an i.p. injection of a specific CCK A (devazepide, 1 mg/kg) or CCK B (CI-988, 1 mg/kg) receptor antagonist, 30 min prior to an i.p. injection of rat recombinant IL-1b (rrIL-1b), 0.5 mg/kg in 0.9% sterile saline/0.01% rat serum albumin. Blood samples were obtained via an indwelling jugular vein catheter, and the plasma levels of the stress hormones ACTH (adrenocorticotropin hormone) and corticosterone analysed over time as an indicator of HPA axis activation. This dose of rrIL-1b resulted in a significant release of ACTH and corticosterone, peaking at 30-60 min, and returning to basal levels by 2 h. Pretreatment with either devazepide or CI-988 had no effect on the rrIL-1b induced ACTH or corticosterone release. In contrast, the same dose of devazepide completely inhibited the ACTH and corticosterone response to i.p. CCK (octapeptide, sulphated form, CCK-8S), 5 mg/kg. It is concluded that CCK receptors are not involved in the hormonal stress response to a submaximal i.p. dose of rrIL-1b.
Systemic administration of the cytokine interleukin-1b (IL-1b) tractus solitarius (mNTS), where general visceral vagal sensory afferent fibres terminate (6, 7). Furthermore, knife cuts of the results in physiological responses characteristic of an immune challenge, including fever (1), anorexia (2), increased sleep (3) direct pathway from the NTS to the PVN attenuated the PVN Fos protein response to i.v. IL-1b, suggesting the importance and hypothalamic-pituitary-adrenal (HPA) axis activation (4, 5). Activation of the HPA axis is a defining feature of a stress of this pathway in the activation of the PVN (6). Although there are still many questions regarding the mechanisms of response, involving activation of the parvocellular neurones of the paraventricular nucleus of the hypothalamus (PVN ), which action of i.v. IL-1b, there is increasing evidence that the integrity of vagal sensory afferent fibres is critical for many of the in turn project via the median eminence to the anterior pituitary gland. There, stimulated corticotrophs release ACTH into the responses observed following i.p. injection of IL-1b, including HPA axis activation (8, 9
). There appears to be some specificity general circulation, which stimulates the release of the stress hormone corticosterone (in rats) or cortisol (in humans) from in the type of vagal afferents involved, since a complete subdiaphragmatic vagotomy, which includes disruption of gastric the adrenal gland.
Recently, a great deal of interest has focused on the role of vagal afferents, appears to be effective in inhibiting the effects of i.p. administration of IL-1, whereas a selective hepatic branch afferent pathways to the hypothalamus in initiating the stress response following an acute immune challenge, such as injection vagotomy is not (8, 10). It has been demonstrated that IL-1 can increase vagal afferent discharge (11), and the presence of of IL-1b. Systemic administration of IL-1b causes a specific pattern of c-fos mRNA and Fos protein expression in areas IL-1 binding sites has been demonstrated on abdominal paraganglia in a number of species, including the rat (12). However, consistent with vagal activation, such as the medial nucleus housed three/cage, under conditions of constant temperature and humidity, their functional role in this model has yet to be demonstrated. on a 12-h light:dark cycle ( lights on 7.00 a.m.) with access to food and water Hence in spite of significant progress in demonstrating neural ad libitum. Animals were allowed to acclimatize to the housing conditions for immune-brain interactions, the actual mechanisms whereby 11-12 days prior to surgery, and were handled daily for 1 week prior to immune factors access and mediate changes in the brain remain surgery. Following surgery to implant i.p. and i.v. catheters, animals were allowed to recover for 3 days. During this time, catheters were flushed daily ill understood. with 0.3 ml saline (i.p.) or 0.2 ml 100 U/ml heparin-saline (i.v.).
A peptide which exhibits some similarity to IL-1b in its behavioural effects is the gastrointestinal hormone cholecystoki- suggestive of a role for CCK in this IL-1 stimulated behaviour (26) . Of particular interest, is the demonstration that systemic
Blood sampling and drug administration (i.v.) administration of IL-1b increases plasma levels of Blood was withdrawn via the i.v. catheter without disturbing the animal. The heparin-saline (15 U/ml ) in the connecting line was withdrawn slowly via a CCK-LI, and increases gastric vagal afferent nerve activity 1-ml syringe until blood was obtained. A second syringe was used to collect partly via stimulation of CCK A receptors (27) . Hence to 300 ml blood, which was then placed on ice in polypropylene tubes containing summarize, the increase in HPA activity following i.p. admin-30 ml EDTA (ethylenediamine tetra-acetic acid ), 20 mg/ml. The first syringe istration of CCK is dependent on vagal afferent stimulation of blood/heparinized saline was re-injected slowly, and an additional 300-400 ml heparinized saline (15 U/ml; room temperature) administered. The and is mediated by CCK A receptors. The increase in HPA total time to take a blood sample was #4 min. Blood samples were spun at axis activity following i.p. injection of IL-1b is at least 4°C, and plasma aliquots stored at −80°C before analysis of ACTH and partially dependent on vagal afferent stimulation. Systemic corticosterone. It was estimated that #1/6 of the total volume of plasma IL-1 (IL-1b i.v. or IL-1a i.p.) increases plasma levels of CCK, collected (#180 ml ) was the EDTA solution, and this was corrected in the and the gastric vagal afferent nerve activity induced by ILhormone assays. Hence for a 50 ml plasma sample, 60 ml of the plasma aliquot was used.
1b i.v. is partly mediated by stimulation of CCK A receptors.
All drugs and their appropriate vehicles were administered via the i.p.
Hence this study was undertaken to test the hypothesis that catheter, in a 1 ml/kg volume. An additional 0.5 ml saline (room temperature) the activation of the HPA axis by i.p. injection of IL-1b is in was administered to allow for the dead space in the connecting line (#0.3 ml ).
part mediated by activation of CCK A receptors (see Fig. 1 ).
The injection procedure took 60-90 s. rrIL-1b, CCK-8S and their vehicles were kept on ice prior to injection (see below for a description of controls run to check for the stress effect of cold injections). Devazepide, CI-988 and their vehicles were administered at room temperature.
Materials and methods

Experiment 1
Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA, USA) were used. All procedures were approved by UCUCA ( University A dose response curve to rrIL-1b was run, to establish a submaximal dose of IL-1b for future experiments. In addition, the possible stress of injection of Committee on Use and Care of Animals, University of Michigan). Rats were F. 1. Schematic diagram to show potential mechanisms (dotted lines) whereby rrIL-1b activates the HPA axis in the rat. A. Pit: anterior pituitary; CRH: corticosterone releasing hormone; NTS: nucleus tractus solitarius; PVN: paraventricular nucleus of the hypothalamus.
cold solution (rrIL-1b, CCK-8S or their vehicles) was assessed, together with involved incubation of the plasma sample (50 ml ), made up to 200 ml with the zero standard, two antibodies: a radiolabelled (125I ) monoclonal antibody, the effect of addition of rat serum albumin to the saline used to dissolve IL1b. In the first part of the experiment, the following groups of animals were which binds to the N-terminal of ACTH, and a biotinylated polyclonal antibody which binds to the C-terminal region of ACTH. In addition, the used: (1): no injection (n=6); (2) 0.9% pyrogen free saline i.p. (n=5); (3) rrIL-1b 0.5 mg/kg i.p. (n=5); (4) rrIL-1b 1 mg/kg i.p. (n=5); (5) rrIL-1b reaction mix was incubated with an avidin-coated bead, used to bind the sandwich complex via an avidin biotin reaction. Since the sandwich complex 2 mg/kg i.p. (n=6); and (6) rrIL-1b 4 mg/kg i.p. (n=4) All doses of rrIL-1b for the first part of the experiment were dissolved in pyrogen-free saline.
requires both C-and N-terminal regions, the radioactivity was proportional to the amount of intact ACTH in the sample, and was calculated by Blood samples were taken immediately prior to the injection (t=0), t=15, 30, 60, 120 and 240'. Samples were taken between 10.00 and 16.00 h. In the comparison with a standard curve. second part of the experiment, the following groups were used: (1) 0.9%
Corticosterone assay pyrogen-free saline with 0.01% rat serum albumin i.p. (saline/rsa; n=3); (2) 0.5 mg/kg rrIL-1b in saline i.p. (n=2); (3) 0.5 mg rrIL-1b in saline/rsa i.p.
The radioimmunoassay for analysis of plasma corticosterone has been (n=3); (4) rrIL-1b 1 mg/kg in saline i.p. (n=3); (5), rrIL-1b 1 mg/kg in described previously (7). Briefly, 5 ml plasma was incubated overnight with saline/rsa i.p. (n=3); and (6) heat inactivated (boiled for 2 h) rrIL-1b 3H-corticosterone and an antibody to corticosterone raised in our laboratory, 0.5 mg/kg in saline/rsa i.p. (n=3). Blood samples were taken immediately in phosphate buffered saline/0.25% bovine serum albumin. Bound vs free prior to the injection (t=0), t=10, 20, 30, 45, 60 and 120. Samples were corticosterone was separated by charcoal extraction, and the amount of taken between 10.00 and 14.00 h.
corticosterone calculated by comparison with a standard curve.
Experiment 2 Statistics
The effect of pretreatment with the CCK A or CCK B receptor antagonists, Results are expressed as mean±SEM throughout. The total area under the devazepide or CI-988, respectively, was investigated. Devazepide was dissolved curve (y=0 baseline) was calculated for ACTH and corticosterone levels to a final concentration of 1 mg/kg/ml in 151:8 dimethylsulphoxide: Tween80: across the sampling time period, using trapezoidal integration (GraphPad 1% carboxymethylcellulose. CI-988 was dissolved in 0.9% pyrogen-free saline Prism). Data were analysed by one-way ANOVA followed by the Tukey postto a final concentration of 1 mg/kg/ml. A baseline blood sample was taken, hoc comparison test. Linear trend analysis was performed for the initial dose and the antagonist or appropriate vehicle administered via the i.p. catheter response curve in experiment 1. For analysis of individual time point data, (t=−30∞). A second blood sample was taken 20 min later. rrIL-1b t-tests were performed. Significance was set at P<0.05. 0.5 mg/kg/ml or vehicle(0.9% pyrogen-free saline/0.01% rat serum albumin) was administered 30 min after the antagonist via the i.p. catheter (t=0∞). In addition, the ability of devazepide to antagonize the stress response to CCK-8S administration was verified. Devazepide (1 mg/kg/ml ) or vehicle there was a slight elevation in corticosterone levels at 240 min (e.g. no injection group rose from 2.0±0.7 at t=0∞ to ACTH assay 5.4±0.9 mg/dl at t=240∞, most likely due to the normal A sandwich radioimmunoassay technique was used to assess plasma levels of ACTH (Nichols Institute Diagnostic Kit, CA, USA). Briefly, the procedure circadian rise, since the last samples were taken between 341±177 pg/ml, respectively, P<0.05 for both doses compared with saline, 22±8.8 pg/ml ), and did not return to
Values represent the mean total area under the curve (AUC ) ± SEM.
basal levels until 240 min. For corticosterone, a similar pattern Data were analysed by ANOVA, followed by Tukey's post-hoc comparto ACTH was observed, but with a slight delay in response.
ison test.
For example, for the 2 mg/kg dose, the peak for ACTH *P<0.05; ‡P<0.001, with respect to appropriate vehicle control group. occurred at 30 min (350±129 pg/ml ), and the levels were in § P<0.05 with respect to 0.5−rsa group. ¶P<0.01, with respect to 1−rsa group. decline at 60 min (257±125 pg/ml ), whereas corticosterone levels were still maximal at 60 min (15.6±2.8 mg/dl at t=30∞, P<0.01 compared with saline 1.5±0.5 mg/dl; 16.8±2.5 mg/dl T 3. Experiment 2a: AUC Over 2 h Sampling Period: at t=60∞, P<0.01 compared with saline 2.3±0.6 mg/dl ). the Effect of Devazepide (DEV ) 1 mg/kg i.p. or Vehicle As was observed for ACTH, the maximal peak for cortico-(DMSO) 30 min Prior to IL-1b 0.5 mg/kg i.p. or Saline/rsa sterone was obtained with doses of 1 mg/kg and higher (Sal+) on ACTH and CORT Levels.
(18.8±2.0 mg/dl at t=30∞ for 1 mg/kg dose, P<0.01 compared with saline), while with increasing doses (2 and 4 mg/dl ), the 
Part 2
The addition of 0.01% rat serum albumin to the saline vehicle
Values represent the mean total area under the curve (AUC )±SEM. Data had no effect on plasma levels of ACTH and corticosterone were analysed by ANOVA, followed by Tukey's post-hoc comparison test. *P<0.01; †P<0.001, with respect to appropriate vehicle control group.
when administered alone (Table 2) . However, when this was used as a vehicle for rrIL-1b, this resulted in at least a doubling of the hormone response, suggesting that the rrIL1b was adhering to the tubing (Table 2) . For example, a 0.5 mg/kg dose rrIL-1b in saline/rsa produced a slightly greater hormonal response than 1 mg/kg rrIL-1b in saline. Since 0.5 mg/kg rrIL-1b in saline/rsa resulted in a submaximal hormonal response, and gave a sharp peak for both ACTH and corticosterone, returning to basal levels by 120 min, this was chosen as the dose against which to run the antagonists. In order to verify that the stress hormone response was not due to a non-specific pathogen in the rrIL-1b preparation, three animals were treated with heat inactivated rrIL-1b, 0.5 mg/kg in saline/rsa. The ACTH and corticosterone responses in these animals were not significantly different from vehicle controls (Table 2) .
Experiment 2
Treatment with either antagonist vehicle (saline or DMSO/ carboxymethylcellulose/Tween80), followed by saline/rsa injection did not result in a significant increase in either ACTH or corticosterone secretion (Tables 3-5 and Figs 2, 3). As expected, the administration of antagonist vehicle followed by rrIL-1b, 0.5 mg/kg (in saline/rsa) i.p. resulted in a significant rise in ACTH (P<0.01, relative to their appropriate vehicle controls) and corticosterone (P<0.001 relative to their appropriate vehicle controls) (Tables 3, 4; Fig. 2 ). Levels of ACTH and corticosterone peaked between 30 and 60 min, and were back to (ACTH ) or approaching (corticosterone) basal levels by 120 min (Fig. 2) . The administration of devazepide 1 mg/kg i.p. (Table 3 , Fig. 2 ) or CI-988 1 mg/kg i.p. (Table 4) 30 min prior to rrIL-1b, 0.5 mg/kg i.p., did not prevent the rrIL-1b-induced rise in ACTH and corticosterone. There were no significant differences across time between the saline/rrIL-1b and CI-988/rrIL-1b groups, or DMSO/rrIL-1b and devazepide/rrIL-1b groups. In contrast, a 30-min pretreatment with the same dose of devazepide completely inhibited the CCK-8S induced rise in ACTH (P<0.01; Table 5 ; Fig. 3 ) and corticosterone (P<0.001; Table 5 ; Fig. 3 ).
Discussion
The possibility that systemic IL-1b activates the HPA axis by a CCK-receptor mechanism was investigated in the present study. No evidence was found to suggest that a submaximal Dev/Sal+ Dev/IL-1b 1b and Dev/IL-1b groups were significantly greater than DMSO/Sal+or Dev/Sal+groups at 30, 45 and 60 min (P<0.01 for all ). At t=120∞, the DMSO/IL-1b group had significantly greater corticosterone than DMSO/ Sal+group, P<0.05. There were no significant differences between DMSO/IL-1b and Dev/IL-1b groups in either ACTH or corticosterone, for total area under the curve, or at any individual time point.
i.p. injection of IL-1b releases ACTH or corticosterone via the activation of CCK receptors, since neither pretreatment with the CCK A receptor antagonist, devazepide, nor CCK B receptor antagonist, CI-988, inhibited the stress hormone response to this peptide. In contrast, the same dose of devazepide completely inhibited the ACTH and corticosterone response to an i.p. injection of CCK-8S. Although the efficacy of CI-988 was not tested in the present study, this compound has nanomolar affinity for CCK B receptors, and has been shown to be effective in animal tests of anxiolytic behaviour with a dose as low as 0.001 mg/kg (29) . Hence it is highly likely that the 1 mg/kg dose employed in this study inhibits the majority of CCK B receptors, but was ineffective in inhibiting the IL-1b-induced stress response. Although our hypothesis did not predict a role for CCK B receptors in the HPA axis response to i.p. IL-1b, we cannot rule out the possibility that an additional subtype of CCK B receptor, at which CI-988 is a less effective antagonist, may be involved in the response (30) .
The lack of effect of devazepide in inhibiting the stress response to IL-1b is in contrast to predicted results. Our original hypothesis was that IL-1b acts via vagal IL-1 receptors, but also causes release of peripheral CCK, which would act on vagal CCK A receptors, with both mechanisms involved in HPA axis activation (Fig. 1) . Our data raise two fundamental questions. The first is whether or not this dose of IL1b is acting via the vagus to elicit HPA axis activation, or whether other mechanisms are more important. Secondly, was CCK in fact released by this dose of IL-1b? To address the first issue, current evidence suggests that the dose of IL1b is important in determining the relative role of the vagus in mediating its effects, with higher doses likely to engage additional mechanisms of action. For example, with high doses, it is probable that IL-1b enters the general circulation in sufficient concentrations to access the brain via alternative routes, such as via the circumventricular organs (31) , by a direct transport mechanism (32), or by causing an inflammatory reaction at the blood brain barrier, resulting in leakiness (33) . There is also evidence that IL-1b can act directly on components of the HPA axis, such as the median eminence (34) . The dose of IL-1b used in the present experiment was chosen because it was submaximal, and gave a sharp peak of ACTH and corticosterone release, returning to basal levels by the end of a 2-h test period. Although not are mediated by capsaicin sensitive vs non-sensitive sensory fibres. Similarly, it is conceivable that different IL-1b-tested directly, this dose of IL-1b (0.5 mg/kg) is almost certainly low enough to be activating the HPA axis via vagal mediated responses may be CCK-dependent or -independent. Colocalization studies for the different subtypes of IL-1 and mechanisms. In published experiments, subdiaphragmatic vagotomies were able to attenuate corticosterone release even CCK receptors in neurochemically identified neuronal populations of the vagus nerve, will provide further insight into after 10 mg/kg i.p. IL-1b (8), ACTH release after 20 mg/kg i.p. IL-1b (9), and to abolish ACTH secretion after 4 mg/kg the neural pathways utilized by IL-1b.
In conclusion, data from the present study provide evidence i.p. IL-1b (9). Hence, evidence to date suggests that for a 0.5-mg/kg dose of IL-1b, it is primarily vagal mechanisms that CCK receptors are not involved in the release of ACTH and corticosterone in response to intraperitoneal administrathat are employed in the stimulation of the HPA axis. With regard to whether CCK was released at this dose of IL-1b, tion of a submaximal dose of IL-1b. the data are less clear. Published data indicate that IL-1a, 4×10.6 D10 units i.p., can increase plasma levels of CCK-LI Acknowledgements (26), although the relationship of the dose used in that study, relative to that used in the present study, is not clear. In physiologically relevant doses, such as the one used in the Accepted 28 January 1999 present study, are sufficient to release CCK, it is clear from the present study that CCK receptors are not involved in the HPA axis response to a submaximal dose of IL-1b. Hence, References regardless of whether or not CCK is released, we believe that activation of CCK receptors is unlikely to be an important following IL-1b pretreatment (36) . Hence, it is possible that
